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Abstract: Alzheimer’s disease is characterized by redistribution of the tau protein pool from soluble
to aggregated states. Aggregation forms proteolytically stable core polymers restricted to the repeat
domain, and this binding interaction has prion-like properties. We have compared the binding
properties of tau and tubulin in vitro using a system in which we can measure binding affinities
for proteins alternated between solid and aqueous phases. The study reveals that a phase-shifted
repeat domain fragment from the Paired Helical Filament core contains all that is required for high
affinity tau-tau binding. Unlike tau-tubulin binding, tau-tau binding shows concentration-dependent
enhancement in both phase directions due to an avidity effect which permits one molecule to bind
to many as the concentration in the opposite phase increases. Phosphorylation of tau inhibits
tau-tau binding and tau-tubulin binding to equivalent extents. Tau-tau binding is favoured over
tau-tubulin binding by factors in the range 19–41-fold, irrespective of phosphorylation status.
A critical requirement for tau to become aggregation-competent is prior binding to a solid-phase
substrate, which induces a conformational change in the repeat domain permitting high-affinity
binding to occur even if tau is phosphorylated. The endogenous species enabling this nucleation
event to occur in vivo remains to be identified. The findings of the study suggest that development
of disease-modifying drugs for tauopathies should not target phosphorylation, but rather should
target inhibitors of tau-tau binding or inhibitors of the binding interaction with as yet unidentified
endogenous polyanionic substrates required to nucleate tau assembly.
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1. Introduction
Alzheimer’s disease (AD) is characterized by an almost complete redistribution of the tau protein
pool from microtubule-bound to an aggregated state taking the form of pathological amorphous
oligomers and paired helical filaments (PHFs) [1]. When the redistribution reaches a level sufficient to
paralyse cytoskeletal transport through loss of microtubule function [2], cytoplasmic assemblies of
PHFs become visible histologically as the neurofibrillary tangles originally discovered by Alzheimer,
thereby giving the disease his name [3]. In clinico-pathological correlation studies, there is a close
relationship between biochemical and histological measures of tau aggregation in post-mortem tissues
and deterioration in mental functioning ante mortem [4], a correlation that holds from the earliest
detectable stages of mental impairment [5]. More recently, the same correlation has been found to
hold during life using positron emission tomography with ligands selective for aggregated tau [6,7].
It would appear plausible, therefore, that a treatment aiming to stop or slow the transfer of tau protein
from the functional to the toxic aggregated state could be beneficial.
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Defining an appropriate pharmaceutical target depends on having a better understanding of
the molecular mechanism underlying this extensive redistribution of the tau protein pool. Many
studies, as reviewed in [5], have shown that tau protein can form polymers in vitro, and it is assumed
that any of these could be used to screen for tau aggregation inhibitors with potential therapeutic
utility [8]. A common view holds that hyperphosphorylation of tau protein is a critical step in the
aggregation cascade. This is based in part on a widely quoted misconception, which has entered the
literature since the papers by Lee, Goedert and colleagues, that PHFs are composed “almost entirely of
hyperphosphorylated tau protein” [9,10]. Phosphorylation of tau inhibits microtubule assembly [11]
and phosphorylation at various sites of tau protein leads to small or major inhibitory effects on tubulin
binding [12,13], that may be overcome by inclusion of appropriate osmolytes [14]. This has led to a
hypothesis widely quoted in the literature that there is an imbalance between kinases and phosphatases
which is disturbed in AD [15,16], leading tau protein to become detached from microtubules, and
secondarily to aggregate. According to this scenario, a tau-based therapeutic approach would seek to
target a kinase particularly responsible for a pattern of phosphorylation causing reduced microtubule
stability. Two compounds, which were shown to reduce tau phosphorylation in cell-based and
transgenic animal models, have been tested in phase 2 clinical trials. These trials were conducted
in progressive supranuclear palsy, a rapidly progressive neurodegenerative disease characterized
by pathological aggregation of tau protein, which is partly phosphorylated. Although the studies
were of adequate size to demonstrate some degree of potential clinical benefit, none was shown
(reviewed in [5]).
There are reasonably good theoretical reasons to have predicted these failures. We have argued
elsewhere on structural and biochemical grounds that less than 5% of the tau molecules making up
the PHF in AD is even N-terminally intact, let alone phosphorylated in domains often considered as
defining the tau pathology of AD [17]. We have also shown previously that the build-up of soluble
hyperphosphorylated tau that is supposed to be a precursor for PHF formation does not actually occur
in the human brain until terminal stages of pathology. Whereas PHF formation can be detected as
early as Braak stage 2 in the neocortex, the build-up of soluble hyperphosphorylated tau is not seen
until Braak stage 6 [18], an interval of some 30 years. Thus, the tendency in the literature to conflate
the concepts “phosphorylated tau” and “PHF tau” (e.g., [15,16]) is likely to be mistaken. Rather, it is
more accurate to consider full-length phosphorylated tau as a “PHF-associated protein”.
It is important, therefore, to address the pathological relevance of the system used to identify
potential therapeutic compounds. The assay we have chosen to develop appears useful in several
respects. We have reported previously that a characteristic feature of the tau aggregation, which occurs
in the AD brain is induction of a 15-residue conformational shift in the binding repeats. Thus, the
N-termini of the tau fragments found in the proteolytically stable structural core of the PHF are located
15-residues C-terminal to the start of the repeats, and have a characteristic C-terminal truncation at
position Glu-391, which is 15-residues C-terminal to the end of the repeats [19]. It is striking that this
fragment and its homologues are nevertheless exactly 3 repeats in length, notwithstanding the phase
shift. We have argued that this phase shift is the hallmark of an induced conformational transition
in the repeat domain, which makes it possible to distinguish pharmaceutically between the normal
tau-tubulin binding interaction, and the pathological tau-tau binding interaction, notwithstanding that
both occur through the repeat domain [19]. The characteristic C-terminal truncation at Glu-391 creates
a neo-epitope that can be detected with a monoclonal antibody (mAb) 423 raised against proteolytically
stable PHF preparations [1,20]. In AD brain tissues, this neo-epitope is available without occlusion in
early pathological tau oligomers, in tau oligomers accumulating in pathological lysosomes (so-called
granulo-vacuolar degeneration), and in end-stage extracellular PHFs [21,22]. In intracellular PHFs,
the epitope is occluded by a coating of full-length hyperphosphorylated PHF-associated tau which
constitutes the proteolytically sensitive fuzzy coat of the PHF [23] and accounts for 5% of its mass [17].
The underlying neo-epitope can be exposed by treatment with formic acid [21,23–25].
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The tau species making up the structural core of the PHF and its oligomeric precursors are
derived from a mixture of the six isoforms of tau containing both 3 and 4 repeats (3R, 4R) derived
from repeats 2/3/4 and repeats 1/3/4 of the 4R and 3R isoforms, respectively. The species derived
from repeats 1/2/3 of the 4R isoform has an equivalent C-terminal truncation conferring on it an
identical gel mobility when released from PHFs [26]. We have shown that these features represent
the footprint of a pathological tau-tau binding interaction which locks the repeat domain into a
characteristic proteolytically stable configuration, and that this binding interaction has prion-like
properties in vitro [27]. This stabilised configuration propagates and amplifies the Glu-391 truncation
through repeated cycles of binding of additional full-length tau and proteolytic digestion in a templated
prion-like manner.
We have used the same experimental system to understand better the determinants of the tau-tau
binding interaction of the structural core of the PHF. One particularly useful feature of this system is
the ability to determine binding affinities separately in aqueous and solid phases. This is important,
as it has been suggested that the kinetic barrier to tau aggregation can be overcome by a nucleation
event of some kind [28–32]. We have sought to determine whether tau-tau binding is enhanced by
providing full-length tau as a binding partner versus binding only via the core tau fragment of the PHF.
Furthermore, we have been able to examine in detail the potential role of (hyper) phosphorylation of
tau protein in driving pathological aggregation of tau protein in both aqueous and solid phases and to
compare this with its effect on the tau-tubulin binding interaction using the same detection system.
By these means, we have aimed to get a better understanding of the critical factors responsible for
pathological aggregation of tau protein with a view to development of pathologically relevant drug
screening assays for optimization of tau aggregation inhibitors.
2. Materials and Methods
Preparation of Tau Protein. Recombinant tau (htau40 (T40), the isoform with 2 N-terminal domains
and 4 repeats in the microtubule-binding domain (2N4R)) and truncated dGA tau (amino acids 297–390
of T40) were prepared as described previously. Tau from rat brain or adult human brain was extracted
with perchloric acid [33,34]. In brief, brain tissue was homogenized in 2.5% perchloric acid (4 mL/g
brain tissue) in the presence of protease inhibitors and phosphatase inhibitors and left on ice for
20 min. It was then centrifuged at 13,000 ˆ g for 10 min. The supernatant fraction was dialyzed against
Tris-HCl (100 mM, pH 7.4) for 3 h at 4 ˝C, then against Tris-HCl (5 mM, pH 7.4) overnight at 4 ˝C.
The dialysate was centrifuged at 13,000 ˆ g. Soluble tau was collected in the supernatant fraction.
Tau protein was also repurified, following hyperphosphorylation in vitro, prior to use in the binding
assays. The nomenclature used for the various tau protein preparations is summarized in Table 1.
Table 1. Nomenclature for tau proteins.
Tau Protein Abbreviation Description
Truncated PHF-core tau dGA Bacterial recombinant human tau, residues 297–390 of2N4R tau isoform [35].
Full-length, non-phosphorylated tau T40 Bacterial recombinant human tau, 441-amino acid 2N4Rtau isoform [33].
Hyperphosphorylated tau T40P T40 tau hyperphosphorylated in vitro [36].
Neonatal rat tau NT Endogenously phosphorylated neonatal rat 3-repeat tau.
Hyperphosphorylated rat tau NTP Rat NT hyperphosphorylated in vitro [36].
Hyperphosphorylation of Tau by Rat Brain Extract. Hyperphosphorylation of tau was carried out
according to Biernet et al. [36] using a rat brain extract containing kinases. About 20 to 50 mg of
tau protein (recombinant or extracted from brain tissue) was used in each phosphorylation reaction.
Kinase buffer (A) contained 20 mM Tris-HCl, 10 mM EGTA, 4 mM DTT, 4 mm MgCl2, 4 mM ATP,
4 mM PMSF, 40 mg/mL pepstatin, 40 mg/mL leupeptin, 40 mg/mL aprotinin and 20 mM okadaic
acid (adjusted to pH 7.4 with 3 M NaOH and 2 M HCl). The final [Na+] and [Cl´] was approximately
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30 mM and 10 mM, respectively; excessive salt was found to inhibit kinase activity. Tau protein was
phosphorylated by incubation of a reaction mixture containing 15 mL of tau protein (1–3 mg/mL),
16 mL of buffer A, and 1 mL of rat brain extract.
SDS Gel Electrophoresis Immunoblotting and Immunoelectronmicroscopy. Standard electrophoresis
and immunoblotting procedures were used as described [23,33,34]. Immunoblots were developed
either with horseradish peroxidase or the ABC kit (Vector Laboratories). The mAbs 7/51, 21/D10,
27/499 and 27/342 were used in the form of undiluted hybridoma culture supernatant fluids. The
mAb AT8 (Innogenetics, Belgium) was used at 1/1000 dilution. The mAb 7/51 recognizes an epitope
in the last tau repeat [20,27]; 27/499 recognizes a human-specific tau segment between residues Gly-14
and Gln-26 [27]; 27/342 recognizes a segment between residues Ser-208 and Pro-251 [27], and have
been described previously. The mAb 21/D10 is an IgM antibody raised against the A68-tau brain
extract [9] by us. Non-Pronase-treated PHFs were incubated with mAbs and immunolabeled with
gold conjugated anti-mouse IgG (whole molecule) as described [23]. Samples were pretreated with
alkaline phosphatase according to [35].
Tau Binding Assay. This was carried out, as described previously [27]. Solid-phase tau was coated
on 96-well poly-(vinyl chloride) microtitre plates in 50 mM carbonate buffer at 37 ˝C for 1 h. The coating
concentration was 0–20 mg/mL (0–1.7 µM). The plate was washed twice with 0.05% Tween 20 at
room temperature, followed by blocking with 2% dried milk (Marvel) in PBST for 1 h at 37 ˝C. After
washing twice with 0.05% Tween 20 at room temperature, aqueous-phase tau was added. This was
diluted in 1% gelatin in PBST, at a concentration of 0–300 mg/mL (0–26 µM). Incubation lasted 1 h at
37 ˝C. The plate was washed twice with 0.05% Tween 20 at room temperature. mAbs 27/499 or 27/342,
diluted with an equal volume of 2% Marvel in PBST, were incubated for 1 h at 37 ˝C. After washing
twice with 0.05% Tween 20 at room temperature, horseradish peroxidase-conjugated goat-anti-mouse
antibody (1/1000 in PBST) was incubated for 1 h at 37 ˝C. The plate was washed and incubated with
substrate solution containing tetramethylbenzidine and H2O2 and the rate of change of absorbance
measured using a Vmax plate reader (Molecular Diagnostics, California) as described previously [37].
Each experiment was performed in triplicate. The experimental design included controls in which
both solid-phase and aqueous-phase tau were omitted, and also with either one of the two omitted.
Data Analysis. This was performed as described previously [27]. The average readings for the rate
of change of absorbance were plotted against the plating- or aqueous-phase concentrations of tau, and
curves were fitted according to the Langmuir equation (formally equivalent to the Michaelis-Menten
equation) with the Kaleidagraph (Synergy, Philadelphia) or SysStat (SPSS Inc., Chicago, IL, USA)
programs using quasi-Newton approximation. All curve-fitting correlation coefficients were greater
than 0.95.
3. Results
3.1. Properties of Antibodies Used to Measure Tau-Tau Binding Interactions
We have used a combination of antibodies to different epitopes spanning the tau protein in order to
measure different combinations of proteins in binding assays. The characterization of these antibodies
on immunoblots is shown in Figure 1. The mAb 7/51 reacts with the central core domain of tau protein
and the epitope is present in all isoforms of tau whether phosphorylated or not. The mAb AT8 was
used as a marker for phosphorylated tau with its epitope dependent on phosphorylation of Ser-202 and
Thr-205 [38]. We have generated a new antibody, mAb 21/D10 raised against hyperphosphorylated A68
tau proteins [31], which reacts with sarkosyl-insoluble tau protein isolated from AD brain tissue protein.
The mAb 21/D10 detected a phosphorylation-dependent epitope which is absent in endogenously
phosphorylated neonatal tau, but is present when neonatal tau has been further phosphorylated in vitro
(Figure 1). Non-Pronase treated PHFs were decorated by mAb 21/D10 but immunoreactivity was
lost following pretreatment with alkaline phosphatase (Figure 1f,g) or after proteolysis with Pronase
(not shown), both conditions in which the structure of the filaments is retained. In addition to the
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altered mobility observed on SDS-PAGE and the increased amount, these phosphorylation-dependent
antibodies confirm that the tau had been hyperphosphorylated in vitro, although the complete extent
of phosphorylation of the many potential sites in tau was not characterized further. The kinase
extract used is known to phosphorylate Ser-262 [12], a site that is effective in detaching tau from
microtubules, but also one that is close to the repeat domain of the protein, and one that has been
shown to prevent the aggregation of tau in vitro [39]. The mAb 27/499 recognises a human-specific
epitope in the N-terminal fragment of human tau that differs notably from tau of other species such
as mouse and rat. The mAb 27/499 did not recognise neonatal tau isolated from rat before or after
phosphorylation in vitro, but recognised tau protein isolated from the brain of normal adult human,
tau protein in the sarkosyl-insoluble extract from AD brain, and recombinant human tau before and
after hyperphosphorylation in vitro. In contrast, mAb 27/342 recognised neonatal rat tau regardless of
whether it had been hyperphosphorylated in vitro; it recognises an epitope that is N-terminal to the
central core domain of tau (residues 208–251, [27]).
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phosphorylated neonatal tau (lane 1), but present following in vitro hyperphosphorylation (lane 2), 
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human tau‐specific mAb 27/499 did not recognise neonatal tau  isolated from rat before (lane 1) or 
after phosphorylation in vitro (lane 2), but recognised tau protein isolated from the brain of normal 
adult  human  (lane  3)  and  in  the  sarkosyl‐insoluble  tau  extract  from AD  brain  (lane  4),  and  the 
recombinant human tau both before (lane 5; T40) and after (lane 6; T40P) hyperphosphorylation in 
vitro; (e) In contrast, mAb 27/342 recognised neonatal rat tau both before (lane 1) and after (lane 2) 
hyperphosphorylation in vitro, but otherwise had a similar  immunoreactive profile to mAb 27/499; 
(f,g) Non‐Pronase  treated PHFs  from AD  brain  tissue were  immunodecorated  by mAb  21/10,  as 
visualized by gold particles. The latter immunoreactivity was abolished by prior treatment of PHFs 
with alkaline phosphatase (AP). 
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Figure 1. I unoreactivity profile for t u antibodies. (a) The mAb 7/51 recognised tau
proteins isolated from the brai f neon tal rat both before (lane 1; NT) and after (lane 2; NTP)
hyperphosphorylation in vitro; (b) endogenously phosphorylated tau (lane 1),
the ext n of which s increased following furthe in vitro ph s rylation (la e 2); (c) The mAb 21/D10
detected a phosphorylation-dependent epitope which is absent in e dogenously phosphorylated
neonatal tau (lane 1), but present following in vitro hyperphosphorylation (lane 2), and s also present
in sarkosyl-insoluble tau pr tein is lated from AD brain tissue (lane 4); (d) The human tau-specific
mAb 27/499 did not recognise neonatal tau isolated from rat before (lane 1) or after phosphorylation
in vitro (lane 2), but recognised tau protein isolated from the brain of normal adult human (lane 3) and
in the sarkosyl-insoluble tau extract from AD brain (lane 4), and the recombinant human tau both
before (lane 5; T40) and after (lane 6; T40P) hyperphosphorylation in vitro; (e) In contrast, mAb 27/342
recognised neonatal rat tau both before (lane 1) and after (lane 2) hyperphosphorylation in vitro, but
otherwise had a similar immunoreactive profile to mAb 27/499; (f,g) Non-Pronase treated PHFs from
AD brain tissue were immunodecorated by mAb 21/10, as visualized by gold particles. The latter
immunoreactivity was abolished by prior treatment of PHFs with alkaline phosphatase (AP).
3.2. Solid-Phase Concentration-Dependent Enhancement of Tau Binding Affinity
A truncated repeat domain tau fragment corresponding to phase-shifted repeats 2/3/4 of the
human 4R tau isoform (one of the 3-repeat species found in the core of the PHF, referred to as “dGA”,
resi ues 297–390 and terminating at Ala-390 [34]) was first plated in the solid-phase (“adsorbed” or
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“ads” species). Full-length, non-phosphorylated recombinant human 2N4R tau (“T40”) was incubated
in the aqueous-phase of the assay (“aqueous” or “aq” species). The nomenclature used is described in
Table 1 and the data obtained for all binding constants defined below are summarised in Table 2.
Table 2. Saturation aqueous- and solid-phase binding constants (nM) for tau-tau binding.
Solid-Phase
Species
Aqueous-Phase
Species
Solid-Phase Species Non-Limiting Aqueous-Phase Species Non-Limiting
N1 Q2 Kd,Aqeous N2 Q1 Kd,Adsorbed
dGA T40 22.8 ˘ 2.8 19.3 ˘ 0.8 21.1 36.3 ˘ 21.4 26.6 ˘ 7.3 31.5
dGA T40P 252.4 ˘ 69.8 220.5 ˘ 66.4 236.5 22.5 ˘ 17.7 34.9 ˘ 8.2 28.7
dGA NT -* - - - - -
NT T40 18.8 ˘ 3.4 22.8 ˘ 9.9 20.8 8.6 ˘ 5.0 7.6 ˘ 1.5 8.1
NT T40P 627 ˘ 131.0 382.1 ˘ 64.2 504.5 39.1 ˘ 4.9 23.8 ˘ 1.4 31.5
NTP T40 754 ˘ 181.0 758.8 ˘ 138.3 756.4 2.2 ˘ 1.3 18.8 ˘ 3.7 10.5
NTP T40P 969.2 ˘ 8.8 1163 ˘ 223 1066.1 86 ˘ 8.0 114.7 ˘ 15.6 100.4
N, Q and Kd values are defined in the accompanying text. * No binding of NT in aqueous phase to dGA
adsorbed in the solid phase.
As seen in Figure 2a, for any fixed plating concentration of adsorbed dGA, the binding data for
aqueous T40 detected by N-terminal tau immunoreactivity (mAb 27/499) can be approximated by the
standard relationship:
B = Bm1¨ [T40]/(Kd1 + [T40]) (1)
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Figure 2. Tau-tau binding through the repeat domain. The truncated repeat domain dGA tau fragment
was adsorbed (“ads.”) to the solid phase at the concentrations indicated and binding of full-length
T40 in the aqueous-phase (“aq.”) measured immunochemically using mAb 27/499. (a) For any fixed
concentration of dGA-ads., binding of T40-aq. could be approximated by a family of Langmuir curves
(Equation (1) in text). Systematic variation in the apparent Bmax (Bm1, (b)) and Kd (Kd1, (c)) values
depended on the concentration of dGA-ads. and could be approximated by the empirical relationships
described by Equations (2) and (3) in the text. Conversely, for any fixed concentration of T40 in
the aqueous-phase, binding could be approximated by a corresponding set of Langmuir curves (d)
(Equation (4) in text). In this case, systematic variation in the apparent Bmax (Bm2, (e)) and Kd (Kd2, (f))
values depended on the concentration of T40 in the aqueous-phase and could be approximated by the
empirical relationships described by Equations (5) and (6) in the text. Correlation coefficients for all
approximations exceeded 0.94.
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The values of the constants Bm1 and Kd1 were found to vary systematically with the concentration
of dGA in the solid phase, according to the following empirically derived relationships:
Bm1 = P1¨ [dGA]/(Q1 + [dGA]) (2)
Kd1 = (M1/[dGA]) + N1 (3)
These relationships, depicted in Figure 2b,c, respectively, demonstrate that the apparent Bmax
values increase, and the apparent Kd1 values decrease, with increasing plating concentrations of
adsorbed dGA, approaching asymptotic values at dGA plating concentrations greater than 400 nM
(the underlying correlation coefficients were in the range 0.94–0.99). As the direct binding of dGA
alone in the solid phase is saturated at plating concentrations greater than 20 nM (Figure 3a,b), these
changes cannot be explained simply by greater concentrations of dGA adsorbed in the solid-phase.
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Figure 3. Non-specific binding of dGA (a) or full-length tau (b) to the solid-phase PVC matrix. Binding
was detected using mAbs 7/51 or 499, respectively. In both instances, saturation of non-specific binding
sites occurred at plating concentrations greater than 20 nM.
3.3. Aqueous-Phase Concentration-Dependent Enhancement of Tau Binding Affinity
Since the binding data exist as a two-dimensional matrix, it is possible to examine binding as a
function of the plating concentration of dGA for any given concentration of T40 in the aqueous phase
(Figure 2d). The binding data could again be approximated by a similar set of relationships to those
shown above. That is, for any fixed concentration of aqueous T40, binding can be expressed as a
function of the concentration of solid-phase dGA according to the standard relationship:
B = Bm2¨ [dGA]/(Kd2 + [dGA]) (4)
Again, the values of the constants Bm2 and Kd2 vary systematically with the concentration of T40
in the aqueous phase as follows:
Bm2 = P2¨ [T40]/(Q2 + [T40]) (5)
Kd2 = (M2/[T40]) + N2 (6)
These relationships, depicted in Figure 2e,f, express the asymptotic effects of
concentration-dependent changes in aqueous T40 such that the higher the concentration of
T40 in the aqueous phase the greater the affinity with which dGA in the solid phase is able to capture
T40 from the aqueous phase. The underlying correlation coefficients are in the same range as above.
Therefore, the property of concentration-dependent enhancement of binding affinity operates in both
solid and aqueous phases.
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3.4. Comparison of Tau-Tau Binding Binding Affinity Constants in Aqueous and Adsorbed Phases
The formal significance of the empirical parameters P, Q, M and N, defined above, can be explained
as follows. By substituting the empirical Equations (2) and (3) into Equation (1), the following results
were obtained:
rdGAsÑ8, BÑP1¨ [T40]/(N1 + [T40]) (7)
rT40sÑ8, BÑP1¨ [dGA]/(Q1 + [dGA]) (8)
Likewise, substituting the empirical Equations (5) and (6) into Equation (4) produces the
following results:
rT40sÑ8, BÑP2¨ [dGA]/(N2 + [dGA]) (9)
rdGAsÑ8, BÑP2¨ [T40]/(Q2 + [T40]) (10)
Since Equations (7) and (10) are formally equivalent, N1 ” Q2. These values represent alternative
empirical estimates of the common underlying affinity constant for binding of T40 in the aqueous
phase to adsorbed dGA in the solid phase when dGA has been plated at a non-limiting concentration.
We denote this value as Kd,Aqueous(dGA/T40). Dissociation constants are given for the aqueous-phase
partner that has been underlined in the pair indicated in parentheses. The similarity of the estimates
provided by N1 (22.8 ˘ 2.8 nM) or Q2 (19.3 ˘ 0.8 nM) can be seen from Table 2. The mean of these two
estimates for Kd,Aqueous(dGA/T40) is 21.1 ˘ 2.9 nM.
Likewise, Equations (8) and (9) are formally equivalent, and N2 ” Q1. These values represent
alternative ways of estimating the common underlying affinity constant for the ability of dGA plated in
the solid phase to capture T40 from the aqueous phase when T40 has been provided at a non-limiting
concentration in the aqueous phase. We denote this value as Kd,Adsorbed(dGA/T40). The similarity of the
estimates provided by N2 (36.3 ˘ 21.4 nM) or Q1 (26.6 ˘ 7.3 nM) can be seen from Table 2. The mean
of these two estimates for Kd,Adsorbed(dGA/T40) is 31.5 ˘ 22.6 nM. The difference between the values for
Kd,Aqueous(dGA/T40) and Kd,Adsorbed(dGA/T40) is not statistically significant (p = 0.324).
3.5. Binding Affinities in the Aqueous Phase Following (Hyper)Phosphorylation of Tau Protein
When recombinant human tau protein was hyperphosphorylated in vitro, the Kd,Aqueous(dGA/T40P)
for T40P binding to adsorbed dGA was 236.5 ˘ 96.3 nM (Table 2), indicating 11-fold inhibition relative
to the non-phosphorylated form, a difference that is significant (p = 0.013).
Experiments were also conducted using newborn tau extracted from newborn rat brains.
Newborn rat brain tau (“NT”) is an endogenously phosphorylated form of predominantly 3-repeat
tau [40,41]. It can be hyperphosphorylated further in vitro (“NTP”) by incubation with a crude
rat brain extract, as shown for example by the acquisition of immunoreactivity recognized by the
phosphorylation-dependent mAb 21/D10 raised against the A68 preparation of sarkosyl-insoluble tau
from AD brain [9] (Figure 1c).
When endogenously phosphorylated NT was incubated in the aqueous-phase with adsorbed
dGA, no binding to adsorbed dGA was detected even at concentrations as high as 1 µM (data not
shown). However, when NT was adsorbed in the solid-phase of the assay, the binding affinity of T40
was experimentally indistinguishable from its binding to adsorbed dGA (Figures 2a and 4a; Table 2;
Kd,Aqueous(NT/T40) = 20.8˘ 10.5 nM; p = 0.511). Therefore, adsorption of NT to the solid-phase substrate
overcomes the inhibitory effect of the endogenous state of phosphorylation in NT hindering its binding
to the repeat domain tau fragment in the solid phase and provides the same binding affinity for T40 as
the dGA repeat domain fragment.
Binding of T40P to adsorbed neonatal tau was inhibited 24-fold relative to binding of T40 to
either adsorbed NT (Kd,Aqueous(NT/T40P) value 504 ˘ 146 nM (Table 2); Figure 4b; p = 0.00048) or
dGA. When newborn rat tau had been hyperphosphorylated prior to plating in the solid phase (NTP),
the Kd,Aqueous(NTP/T40) value for binding of T40 was 756˘ 228 nM (36-fold inhibition; Table 2; Figure 5a;
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p = 0.00063). The corresponding Kd,Aqueous(NTP/T40P) value for binding hyperphosphorylated T40P
was 1066 ˘ 223 nM, indicating 50-fold inhibition (Table 2; p < 0.0001).
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Figure 4. Intrinsic inhibitory effects of phosphorylation. Binding of T40 and T40P in the aqueous-phase
to adsorbed neonatal tau (“NT”; (a,b)) or adsorbed depolymerised bovine tubulin (c,d) at the plating
concentrations indicated. Although NT in the aqueous-phase did not bind to solid-phase dGA (data
not shown), binding of T40 (a) to NT was indistinguishable from that seen with dGA in the solid-phase.
Binding was inhibited by a factor of 24-fold following in vitro hyperphosphorylation of recombinant
tau (“T40P”; (b)). Binding of recombinant human tau to depolymerised bovine tubulin (c) was likewise
inhibited by a factor of 24-fold following hyperphosphorylation of tau in vitro (d). Tau binding was
detected using mAb 27/499.
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Figure 5. Induced inhibitory effects of tau phosphorylation. (a) Representative binding curves for
nonphosphorylated T40 to adsorbed neonatal NT or NTP. Binding data is shown only for the case in
which adsorbed neonatal tau was present at saturating concentration (>0.54 µM) but, for calculation of
the Kd values shown here and in Table 2, binding was measured over the full range of NT concentrations
shown in Figure 4. Prior hyperphosphorylation of neonatal tau (adsorbed NTP) inhibited binding of
T40 in the aqueous-phase by a factor of 36-fold; (b) Representative curves for binding of adsorbed NT
at saturating concentrations of T40 or T40P (>654 µM and >4362 µM, respectively). The corresponding
solid-phase binding constants calculated from data obtained over the full range of aqueous-phase tau
concentrations are shown. The effect of hyperphosphorylation of tau in the aqueous-phase is to reduce
the binding affinity of the adsorbed species by a factor of 3-fold.
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3.6. Binding of Phosphorylated or Non-Phosphorylated Tau in the Aqueous Phase to Depolymerized Tubulin
For comparison, the affinity for binding of tau in the aqueous phase to depolymerized bovine
tubulin in the solid phase was Kd,Aqueous(Tub/T40) = 403˘ 86 nM. The corresponding Kd,Aqueous(Tub/T40P)
value for T40P was 9583˘ 3227 nM, indicating a 24-fold inhibition following tau hyperphosphorylation
(p = 0.0022) (Figure 4).
3.7. Solid-Phase Binding Constants in the Presence or Absence of Hyperphosphorylation
As shown above, it is possible to calculate the solid-phase binding constant which describes the
affinity with which tau protein in the adsorbed state is able to capture tau protein from the aqueous
phase when the latter is available at non-limiting concentration. The affinity of dGA in the solid
phase for binding T40P in the aqueous-phase (Kd,Adsorbed(dGA/T40P)) was 28.7 ˘ 19.5 nM, despite the
11-fold difference in the corresponding aqueous-phase binding constant seen in the same experiment
(Table 2). The similarity in the binding affinity of dGA in the solid-phase for capture of either T40
(Kd,Adsorbed(dGA/T40) = 31.5 ˘ 22.6 nM) or T40P (Kd,Adsorbed(dGA/T40P) = 28.7 ˘ 19.5 nM) in the aqueous
phase can be seen in (Table 2; p = 0.537).
Similar results were also obtained when full-length newborn rat tau protein was used
as the absorbed species, either in the native state of phosphorylation (NT) or following its
further hyperphosphorylation in vitro (NTP). For NT (Kd,Adsorbed(NT/T40) = 8.1 ˘ 5.2 nM) or NTP
(Kd,Adsorbed(NTP/T40) = 10.5˘ 3.8 nM) adsorbed in the solid phase, the affinities for capture of T40 in the
aqueous-phase at non-limiting concentration (Figure 5b; Table 2) were essentially identical (p = 0.356).
The only instances where adsorption in the solid phase did not entirely negate the inhibitory effect
of (hyper)phosphorylation in neonatal tau, as seen via the solid-phase binding constant, were those
where the aqueous-phase species was itself hyperphosphorylated. Thus, the binding affinity of NT
adsorbed in the solid phase for capture of T40P from the aqueous phase was 3-fold less than for T40 in
the aqueous phase (Table 2; Kd,Adsorbed(NT/T40P) = 31.5 ˘ 5.1 nM; Kd,Adsorbed(NTP/T40) = 10.5 ˘ 3.8 nM;
Figure 5b; p = 0.00048). The binding affinity of NTP adsorbed in the solid phase for capture of T40P
was 10-fold less than for T40 (Table 2; Kd,Adsorbed(NTP/T40P) = 100.4 ˘ 17.5 nM; Kd,Adsorbed(NTP/T40) =
10.5 ˘ 3.9 nM; p < 0.0001).
4. Discussion
4.1. Features of the Tau-Tau Binding Assays
The present study shows that the tau-tau binding interaction through the repeat domain has
several unexpected properties. A particularly useful feature of the assay configuration and analytical
methodology we have used in this study is that it provides a means for elucidating binding properties
in both solid and aqueous phases. This in turn makes it possible to examine separately the effect on
tau-tau binding of prior adsorption to a solid-phase substrate, the effect in both phases of chemical
modification of tau by means of phosphorylation, and to compare these properties with corresponding
effects on the physiological tau-tubulin binding interaction. This can all be achieved in the same assay
configuration and using the same antibody to detect the binding interaction.
All of the binding data can be described in a surprisingly consistent manner by a system of typical
Langmuir equations. This in turn implies that the tau-tau binding interaction is competitive, saturable
and reversible. For any given set of conditions, binding can be defined quantitatively by a binding
constant (Kd) and a saturation binding value (Bmax). For the tau-tau binding interaction to be described
systematically in this way, the following assumptions must be met: (1) for any given set of conditions,
individual binding sites operate independently of one another (i.e., there is no positive or negative
cooperativity between them); (2) the number of binding sites is finite; and (3) binding is reversible, with
on and off rates that are determined entirely by the relative concentrations of the interacting species.
The absence of cooperativity is supported by the data fitting well to the Langmuir equation with the
Hill coefficient set to one, with correlation coefficients greater than 0.94. The implied reversibility has
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particular theoretical importance in that it contradicts claims (also based on in vitro binding data) that
the formation of covalent bonds via cysteine residues is necessary to support tau-tau binding through
the repeat domain [42]. This is further supported by a recent report that the formation of fibrils from a
Tau208-324 fragment does not depend upon cross-linking between cysteine residues [43].
4.2. The Binding Characteristics for Tau in Solid and Aqueous Phases
For any given plating concentration of the repeat-domain dGA fragment in the solid phase,
binding of full-length, non-phosphorylated 4-repeat tau (T40) presented in the aqueous phase can be
described by characteristic values for Kd1 and Bm1. The value for Bm1, which is the maximum readout
of the assay as the concentration of T40 approaches saturation, represents a measure of the maximum
number of binding sites provided by dGA in the solid phase at a given plating concentration for
capture of T40 from the aqueous phase. The dependency of the Kd1 of the aqueous species on the
plating concentration of dGA in the solid phase indicates that that, at low plating concentrations of
solid-phase dGA, T40 binds with low affinity, even when T40 is available at non-limiting concentration
in the aqueous phase. As [dGA]Ñ8 the Kd1 value drops to a limiting asymptotic value which we
denote N1. It can be shown that this asymptotic value is the same as Q2, which is the affinity constant
calculated from data expressed as dGA capture of T40 when [dGA]Ñ8 at varying concentrations of
T40 and determined as Bm2 (i.e., Bmax). N1 and Q2 therefore represent alternative ways of estimating
the same underlying limiting value for Kd,Aqueous (dGA/T40) for binding of T40 in the aqueous phase as
[dGA]Ñ8, for which the mean value is 21.1 ˘ 2.9 nM.
It is also possible to examine the capture of aqueous phase T40 by solid-phase dGA at a fixed
concentration of T40 but at varying concentrations of dGA. For a given concentration of T40 in the
aqueous phase, the amount of T40 captured at different concentrations of solid-phase dGA can be
described by a similar set of Langmuir equations, each with its apparent Kd2 and Bm2 values. The
values of Kd2 decrease with increasing concentrations of T40 to an asymptotic value as [T40] Ñ 8,
which we denote by N2. As above, it can be shown that this asymptotic value is formally the same
as Q1. The empirical parameters N2 and Q1 therefore represent alternative ways of estimating the
same underlying limiting value for Kd,Adsorbed (dGA/T40) for capture, by solid phase dGA (underlined),
of T40 from the aqueous phase as [T40]Ñ8, for which the mean value is 31.5 ˘ 22.6 nM.
The concentration-dependent enhancement in binding affinity implies that there is an avidity
effect, and the phase reciprocity of the phenomenon implies that it operates in both phases. This avidity
effect is most likely due to the closer alignment of dGA molecules with increasing concentration, such
that each molecule of T40 may interact with more than one molecule of dGA. For this effect to be
observed maximally, solid-phase concentrations of dGA must approach 400 nM. This cannot be due
to a concentration-dependent increase in the actual amount of dGA on the solid phase, since dGA
binding to the plate saturates at concentrations greater than 20 nM. Furthermore, the critical incubation
concentration of T40 in the aqueous phase when this effect is observed is only ~20 nM. This disparity
in concentrations supports the interpretation that each T40 molecule in the aqueous phase is able to
bind to many dGA molecules in the solid phase (i.e., “one-to-many” binding).
It is surprising that the same avidity effect must also operate in the aqueous phase, whereby dGA
molecules adsorbed in the solid phase are able to capture T40 from the aqueous phase with higher
affinity as the incubation concentration of T40 increases. Again, this is most likely due to a closer
alignment or packing with increasing concentration of T40 molecules in the aqueous phase such that
each molecule of dGA is able to interact with more than one molecule of T40 in the aqueous phase.
This is consistent with the increase in Bm2 values with increasing concentrations of T40. For this effect
to be observed maximally, the incubation concentrations of T40 must approach 250 nM, whereas the
critical plating concentration of dGA when this effect is observed is ~30 nM. This again supports the
interpretation that avidity is explained by the capacity for one molecule in the solid phase to bind to
many in the aqueous phase.
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4.3. Impact of Phosphorylation on Binding Characteristics
The reciprocity of the aqueous- and solid-phase relationships breaks down when one or both
binding partners are hyperphosphorylated. The aqueous-phase binding affinity of T40 to endogenously
phosphorylated full-length neonatal tau (NT) in the solid phase is identical to the binding affinity of T40
to dGA in the solid phase. This implies that the dGA fragment encompassing only the phase-shifted
version of repeats 2/3/4 contains all that is needed for binding of T40, and that neither provision
of a full-length tau molecule in the solid phase not its endogenous state of phosphorylation have
any impact on the aqueous-phase binding affinity. However, binding of phosphorylated T40P in the
aqueous phase to adsorbed dGA is inhibited 11-fold relative to the binding of T40 to dGA. When
NT in the solid phase is hyperphosphorylated to NTP, binding of non-phosphorylated T40 in the
aqueous phase was inhibited 36-fold relative to its binding to NT. If, in addition, T40 is phosphorylated
to T40P, its binding to NTP in the solid phase is inhibited 50-fold relative to binding of T40 to NT.
Thus, whereas provision of NT in its endogenous state of phosphorylation in the solid phase does not
enhance capture of T40 from the aqueous phase, any further phosphorylation of either the solid- or
aqueous-phase species produces a substantial hindrance to binding.
The inhibitory effect of phosphorylation of the aqueous-phase species on its binding to dGA
occurs despite plating of dGA at a concentration which ought otherwise to enhance binding due
to the avidity effect described above. T40P molecules in the aqueous phase are inherently less able
to bind to dGA in the solid phase. This is most likely due to stabilization of a conformation in the
aqueous phase which impedes access to the critical repeat domain-binding region. The most striking
instance of this is the endogenous state of phosphorylation of NT in the aqueous phase, which entirely
blocks its ability to bind through the repeat domain even at high concentration (i.e., up to 1 µM). This
presumably represents an adaptation preventing initiation of the tau aggregation cascade during a
period of intense developmental plasticity. The same phenomenon can be seen to operate for T40
binding to tubulin whereby, in the hyperphosphorylated state, the binding affinity of T40P is reduced
by a factor of 24-fold. This is in line with observations previously reported [17,39,44,45].
The inhibitory effect of phosphorylation can be seen even if the species in the aqueous
phase is not itself phosphorylated. Thus, as noted above, binding of non-phosphorylated T40 to
hyperphosphorylated NTP on the solid phase is inhibited 36-fold relative to its binding to endogenously
phosphorylated NT on the solid phase. This suggests that even in the adsorbed state and availability at
concentrations where [NTP]Ñ8, hyperphosphorylation of neonatal tau prevents it from entering into
the alignment/packing interactions in the solid phase required to support the avidity effect discussed
above, which is required for high affinity binding of T40.
It is surprising to find that the solid-phase binding constant for dGA is unaffected by the
state of phosphorylation of the aqueous-phase species. Thus the values for Kd,Adsorbed (dGA/T40)
and Kd,Adsorbed (dGA/T40P) are indistinguishable, notwithstanding the 11-fold increase in the value of
the aqueous-phase binding constant (i.e., Kd,Aqueous (dGA/T40P) = 11 ˆ Kd,Aqueous (dGA/T40)). Since the
asymptotic solid-phase binding constant is determined when the concentration of the aqueous-phase
species is non-limiting, the implication is that the impediment to alignment/packing caused by
phosphorylation has a reversible conformational character that can be overcome at a sufficiently
high concentration of the aqueous-phase species. Similarly, the values for Kd,Adsorbed (NT/T40) and
Kd,Adsorbed (NTP/T40) are indistinguishable. That is, provided the species in the aqueous phase (T40)
is not phosphorylated, hyperphosphorylation of neonatal tau adsorbed to the solid phase makes no
difference to the solid-phase binding constant. Furthermore, the identity of the solid-phase binding
constants for binding either T40 or T40P in the aqueous phase implies that phosphorylation does
not change the sites in the tau molecule required for high affinity binding. The constancy of the
solid-phase binding constants appears at first site to contradict the finding that hyperphosphorylation
of neonatal tau in the solid-phase impairs the aqueous-phase binding affinity of T40 by a factor of
36-fold. However, the solid-phase binding constant is determined as [T40]Ñ8 in the aqueous phase.
In other words, the concentration-dependent alignment or packing of T40 molecules in the aqueous
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phase required to support the avidity effect is able to occur at a sufficiently high concentration of the
aqueous phase species.
4.4. Effect of Regions Outside the Repeat Domain on Binding
If the species in the aqueous phase is phosphorylated to T40P, the value for Kd,Adsorbed is increased
three-fold for NT in the solid phase, and 10-fold for NTP in the solid phase. As discussed above in the
case of dGA in the solid phase, phosphorylation of the aqueous-phase species makes no difference to
the solid-phase binding constant. A possible explanation is that as either [T40]Ñ8 or [T40P]Ñ8 in
the aqueous phase, the unfavorable conformation produced in the aqueous phase by phosphorylation
is overcome, and solid-phase binding at the critical concentration (i.e., ~30 nM) is able to benefit via
the one-to-many mechanism underlying avidity. However, when the species in the aqueous phase is
phosphorylated (T40P) and the species in the solid phase is either endogenously phosphorylated (NT)
or hyperphosphorylated (NTP), some further factor associated with regions outside the repeat domain
increases the solid-phase binding constant. This effect must pertain to regions of the molecule outside
the repeat domain, since the effect is not seen with dGA in the solid phase. The factor most likely to be
responsible is a net charge effect, whereby the presence of phosphate groups in regions outside the
repeat domain, in both solid- and aqueous-phase binding partners, simply produce a direct inhibition
that is not mediated via conformation.
Regions outside the repeat domain are nevertheless able to contribute strongly to the solid-phase
binding affinity. This is based on the observation that, provided the species in the aqueous phase
is non-phosphorylated T40, the values of the solid-phase binding constant for NT or NTP are
one third that for dGA in the solid phase (i.e., the values for Kd,Adsorbed (NT/T40) = 8.1 ˘ 5.2 nM
and Kd,Adsorbed (NTP/T40) = 10.5 ˘ 3.9 nM are one third of Kd,Adsorbed (dGA/T40) = 31.5 ˘ 22.6 nM).
Therefore, the additional regions outside the repeat domain appear to provide a further binding
advantage in the solid phase. In this configuration, avidity is presumed to be operating in the
aqueous phase as [T40]Ñ8, permitting one-to-many binding to occur for either NT or NTP at the
critical concentration in the solid phase (i.e., ~10 nM). One possible explanation might be considered
to relate to the fact that the repeat domain of neonatal tau comprises repeats 1/3/4, whereas the
dGA fragment comprises the phase-shifted version of repeat 2/3/4. However, as noted earlier, the
aqueous-phase affinity constants for binding of T40 to dGA or NT in the solid phase are identical
(i.e., Kd,Aqueous (dGA/T40) = 21.1 ˘ 2.9 nM and Kd,Aqueous (NT/T40) = 20.8˘ 10.5 nM). The difference in the
repeat domains is therefore unlikely to be the explanation. A more plausible alternative is that binding
of regions of the tau molecule outside the repeat domain to the plate further facilitate acquisition
of the optimal configuration required for tau-tau binding at the critical solid-phase concentration.
For example, in the case of dGA, plate binding and tau-tau binding must occur through the same
domain, whereas if NT or NTP is provided, the adsorption interaction may be mediated by domains
outside the repeat domain, leaving the repeat domain with greater freedom to associate.
4.5. Tau-Tubulin Interactions
In contrast to the complexities of tau-tau binding, the tau-tubulin binding interaction appears
to be much simpler. First, no avidity effect was seen. Providing tubulin in the solid phase at higher
concentration did not enhance tau-tubulin binding. The value of Kd,Aqueous (Tub/T40) remained constant
irrespective of the solid-phase concentration of tubulin. Second, as noted already, the effect of
phosphorylation of tau was comparable in both tau-tubulin and tau-tau binding interactions. For
tau-tubulin binding, phosphorylation produced a 24-fold inhibition following tau phosphorylation.
For tau-tau binding, phosphorylation also produced an 11- to 50-fold inhibition of binding, depending
on the exact configuration. However, tau-tau binding was favored over tau-tubulin binding by a
factor of 19-fold if tau is non-phosphorylated (21.1 ˘ 2.9 nM vs 403 ˘ 86 nM, respectively, for T40
binding to dGA or tubulin in the solid phase) and 41-fold if tau is phosphorylated (236.5 ˘ 96.3 nM
vs. 9583 ˘ 3227 nM, respectively, for T40P binding to dGA or tubulin in the solid phase). There is,
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therefore, no need to invoke phosphorylation as a mechanism to explain detachment of tau from
microtubules and the 80-fold redistribution of the tau pool from tubulin-bound to aggregated forms
that is seen in AD [1]. Once either full-length tau or the truncated repeat-domain fragment are
available bearing conformational changes similar to those produced by adsorption in the solid-phase,
the inherent tau-tau binding affinities will drive a progressive redistribution of the tau protein pool
away from tubulin-bound towards the aggregated state. We have shown previously, in a biochemical
study of progression of tau aggregation in the human brain, that the loss of soluble tau (released from
depolymerized microtubules) is not sufficient to explain the accumulation of aggregated tau in the
AD brain. Rather, there appears to be increased synthesis of new tau to compensate for the continued
loss of soluble tau through aggregation [45]. This continues until a point is reached where the overall
rate of aggregation exceeds the ability of the neuron to compensate by synthesis of new tau protein.
It is only at this relatively late stage that tau aggregation becomes visible histologically in the form of
neurofibrillary tangles, a stage that in the neocortex typically occurs some 20 years after onset of tau
aggregation [17,46].
4.6. Therapeutic Implications
From this study, it appears that the most important factor required for conversion of tau protein
from non-aggregating to aggregating states is to possess a conformational change similar to that which
is induced by binding to a solid-phase polyanionic substrate (“PAS”) analogous to the poly(vinyl
chloride) plate present in our assay. This process does not depend upon prior post-translational
modifications such as hyperphosphorylation (e.g., [12,13]) or proteolytic truncation (e.g., [47,48]) as
essential initiating events, nor does the critical pathological interaction require to be stabilized by
formation of covalent bonds at cysteine residues as has been suggested [42,49]. Once the pathological
solid-phase configuration of the repeat domain has been acquired, further tau aggregation can then be
driven by high-affinity binding interactions which are self-replicating and self-amplifying [27]. The
resulting aggregate is proteolytically stable and self-propagating, i.e., prion-like [19].
In AD, neurofibrillary lesions first appear in locus coeruleus and entorhinal cortex, followed by
hippocampal formation and large parts of the neocortex [50,51]. There is now further evidence from
cellular and mouse models that assembled tau can behave like a prion, with the intercellular transfer of
tau oligomers that can become self-propagating [52] and are capable of passage of aggregated tau from
transgenic mice [53–56]. Distinct conformers of assembled tau [53,57–59] akin to prion strains, may
help account for the selective neuronal vulnerability characteristic of specific tauopathies other than
AD [60,61]. The active conformations may also offer potential for immunotherapeutic approaches in
the treatment of tauopathies [62]. Although there is much yet to be understood about the mechanisms
of transmission of tau pathology [60], our findings do not support a direct role for phosphorylation in
this process.
From examination of all the binding configurations available for analysis in this study, the lowest
value binding constant is Kd,Adsorbed (NT/T40) = Kd,Adsorbed (NTP/T40) = ~10 nM. This represents the
minimum energy configuration required to trigger the tau aggregation cascade, and represents the
solid-phase binding constant for full-length neonatal tau (whether or not hyperphosphorylated) bound
to a PAS binding to full-length non-phosphorylated adult tau available at non-limiting concentration
in the aqueous phase. For reasons of assay consistency required to make comparisons, the only
species examined in the solid phase (other than dGA) was neonatal tau, because both lack the
human-specific, N-terminal epitope recognized by mAb 27/499 used in the detection of T40 binding.
Nevertheless, there is no reason to think that full-length adult tau in the solid phase would behave any
differently, given that T40 binding to the truncated dGA fragment from 4-repeat tau and neonatal tau
were indistinguishable.
Based on data from the present study, the “optimal” sequence of events required to initiate
pathological aggregation of tau protein is summarized schematically in Figure 6. In vitro, tau
aggregation can be facilitated by PASs, such as heparin or RNA [30,32,63] or by poly(vinyl chloride),
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as demonstrated here. The substrate that initiates the capture of tau in AD is not known, but
proteins and/or macromolecular complexes that escape normal endosomal/lysosomal processing
could provide an endogenous substrate to trigger/nucleate the pathological tau aggregation cascade
in the AD brain [19]. In our view, therefore, the search for disease-modifying drugs for AD should be
directed not only at inhibitors of tau-tau aggregation, but also on the identification and characterization
of critical PASs in vivo and the screening for drugs which either block the formation of the substrate or
interfere with the interaction between tau and the PAS, which drives downstream tau-tau aggregation.
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may  be  formed  from  macromolecular  complexes  which  escape  normal  endosomal/lysosomal 
processing with advancing age; (ii) The tau bound to a solid‐phase substrate is able to capture further 
full‐length tau through a tau‐tau binding interaction which has greater affinity (lower energy) than 
the  physiological  tau‐tubulin  binding  interaction;  (iii)  This  locks  the  repeat  domain  into  a 
proteolytically  stable  configuration  such  that proteolytic  cleavage of  the N‐  and C‐termini  leaves 
behind a characteristic tau fragment restricted to the repeat domain, the core tau unit of the PHF; (iv) 
The  oligomeric  form  of  truncated  tau  is  able  to propagate  capture  and proteolytic processing  of 
further tau, and repeated cycles of binding and proteolysis result in accumulation of PHF‐core tau; 
(v)  It  is only at a  later  stage  that non‐proteolysed,  full‐length  tau molecules are added and  these 
become  secondarily  phosphorylated.  The  optimal  points  of  pharmaceutical  intervention  are 
therefore  blocking  the  binding  of  tau  to  the  initiating  endogenous  substrate  or  blocking  the 
propagation of tau aggregation cascade with tau aggregation inhibitors. 
5. Conclusions 
We have examined in vitro tau‐tau binding interactions using a system in which we can observe 
the impact of tau binding to a solid‐phase substrate and determine how phosphorylation modulates 
this process. Our findings indicate that prior binding of tau to a solid‐phase polyanionic substrate is 
the critical  factor  in  initiating  the aggregation of  tau protein. This process does not depend upon 
post‐translational  modification,  such  as  tau  phosphorylation.  This  has  direct  implications  for 
targeting pharmaceutical  intervention  in AD  and  other  tauopathies. Blocking  tau  aggregation  in 
these disorders  requires  inhibition of either  the  capture of  tau by, as yet, unidentified protein or 
macromolecular complexes, or the subsequent tau aggregation cascade. 
Acknowledgments: Depolymerised bovine  tubulin was kindly donated by  J. Kilmartin  (MRC Laboratory of 
Molecular Biology, Cambridge). This work was supported by the Medical Research Council (UK), a Wellcome 
Trust Studentship to RL, the Leopold Muller Estate, and the Newton Trust (Trinity College, Cambridge). We 
gratefully acknowledge Academic Books for permission to use Table 2 and Figures 2–4, which correspond to 
Table 1 and Figures 20–22 from Wischik C.M., Lai, R.Y.K. and Harrington, C.R. Modelling prion‐like processing 
of tau protein in Alzheimer’s disease for pharmaceutical development, in Brain Microtubule Associated Proteins: 
Modifications in Disease, Avila,  J.; Brandt, R.; Kosik, K.S., Eds. Harwood Academic Publishers: Amsterdam, The 
Netherlands, 1997. 
Author  Contributions:  All  authors  contributed  to  the  design  of  the  study  and  in  the  preparation  of  the 
manuscript. Robert Lai performed the experiments and Robert Lai and Claude Wischik analysed the data. 
Conflicts of Interest: The authors declare no conflict of  interest. Charles Harrington (Chief Scientific Officer) 
and Claude Wischik (Executive Chairman) are officers in TauRx Therapeutics Ltd and both are co‐inventors on 
various patents related to tau protein. 
  
Figure 6. Schematic representation of tau-tau binding. (i) Tau is initially captured by binding to
a solid-phase substrate. The identity of the endogenous substrate in the aging brain is unknown,
but may be formed from macromolecular complexes which escape normal endosomal/lysosomal
processing with advancing age; (ii) The tau bound to a solid-phase substrate is able to capture further
full-length tau through a tau-tau binding interaction which has greater affinity (lower energy) than the
physiological tau-tubulin binding interaction; (iii) This locks the repeat domain into a proteolytically
stable configuration such that proteolytic cleavage of the N- and C-termini leaves behind a characteristic
tau fragment restricted to the repeat domain, the core tau unit of the PHF; (iv) The oligomeric form of
truncated tau is able to propagate capture and proteolytic processing of further tau, and repeated cycles
of binding and proteolysis result in accumulation of PHF-core tau; (v) It is only at a later stage that
non-proteolysed, full-length tau molecules are added and these become secondarily phosphorylated.
The optimal points of pharmaceutical intervention are therefore blocking the binding of tau to the
initiating endogenous substrate or blocking the propagation of tau aggregation cascade with tau
aggregation inhibitors.
5. Conclusions
We have examined in vitro tau-tau binding interactions using a system in which we can observe
the impact of tau binding to a solid-phase substrate and determine how phosphorylation modulates
this process. Our findings indicate that prior binding of tau to a solid-phase polyanionic substrate
is the critical factor in initiating the aggregation of tau protein. This process does not depend upon
post-translational modification, such as tau phosphorylation. This has direct implications for targeting
pharmaceutical intervention in AD and other tauopathies. Blocking tau aggregation in these disorders
requires inhibition of either the capture of tau by, as yet, unidentified protein or macromolecular
complexes, or the subsequent tau aggregation cascade.
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